GOTHENBURG, Sweden, May 2, 2024 /PRNewswire/ -- Vitrolife AB (publ) today signed an agreement to acquire 100% of the shares in eFertility (STB Zorg B.V.). This acquisition is a key element of the Vitrolife Group's strategy to bring increased standardisation and digitalisation to IVF clinics around the world..

2024年5月2日，瑞典哥德堡/新闻通讯社/--维特罗夫公司（publ）今天签署协议，收购eFertility（STB Zorg B.V.）100%的股份。此次收购是维特罗夫集团战略的一个关键因素，该战略旨在为世界各地的试管婴儿诊所带来更多的标准化和数字化。

eFertility is an innovative system and software company transforming IVF clinic management with its cutting-edge solutions: eWitness (witnessing system to track and trace each step of the IVF procedure) and eBase (a specialised EMR that is compatible with hospital information systems). eFertility has a leading presence in the Netherlands and is rapidly expanding across Europe.

eFertility是一家创新的系统和软件公司，通过其尖端的解决方案改变了IVF诊所的管理：eWitness（跟踪和追踪IVF程序每个步骤的见证系统）和eBase（与医院信息系统兼容的专业EMR）。eFertility在荷兰拥有领先地位，并正在欧洲迅速扩张。

In 2023, the company had revenues of EUR 1.5 million with a strong sales pipeline demonstrating the increased demand for witnessing systems in the IVF market..

2023年，该公司收入150万欧元，销售渠道强劲，表明体外受精市场对见证系统的需求增加。

The initial purchase price, on a net debt free basis is EUR 9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of EUR 8.4 million. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group's cash.

在无债务的基础上，初始购买价格为960万欧元，将在交割时支付。此外，还有一个以扩大规模和实现销售增长里程碑为基础的盈利部分，为期3年，最高支付840万欧元。预计交割时间为2024年5月中旬，将通过维特罗夫集团的现金进行融资。

eFertility will be reported under the Technologies business area..

eFertility将在技术业务领域报告。

The Vitrolife Group is executing on a new five-year corporate strategy, an important element of which is to build an end-to-end platform connecting the products and services across the entire IVF workflow. The eFertility witnessing system and EMR are core elements of that strategy and combined with the rest of the Vitrolife Group portfolio uniquely position the company to be at the forefront of innovation and automation in IVF clinics around the world..

Vitrolife集团正在执行一项新的五年企业战略，其中一个重要因素是建立一个端到端平台，将整个IVF工作流程中的产品和服务连接起来。eFertility见证系统和EMR是该战略的核心要素，与Vitrolife集团投资组合的其他部分相结合，使该公司处于全球IVF诊所创新和自动化的前沿。

'The acquisition of eFertility represents a significant step in the Vitrolife Group's strategy to transform and digitalise the IVF patient journey. By incorporating eFertility's technologies into our platform, we are making critical advancements towards the development of a seamlessly integrated and more efficient clinic workflow,' said Bronwyn Brophy O'Connor, CEO of Vitrolife Group..

“获得eFertility是Vitrolife集团改造和数字化IVF患者旅程战略的重要一步。Vitrolife集团首席执行官布朗温·布罗菲·奥康纳（BronwynBrophyO'Connor）说，通过将eFertility的技术整合到我们的平台中，我们正在朝着无缝集成和更高效的诊所工作流程的发展取得重大进展。

Jan-Willem Broekman, CEO of eFertility, shared, 'Joining the Vitrolife Group opens an exciting chapter for eFertility. Together, we will continue to push the boundaries of innovation, delivering integrated solutions that address the evolving needs of IVF clinics worldwide.'

eFertility首席执行官扬·威廉·布罗克曼（JanWillemBroekman）分享道：“加入维特罗利集团为eFertility开启了激动人心的篇章。我们将共同推动创新的边界，提供综合解决方案，满足全球试管婴儿诊所不断变化的需求。”